

Clinical Policy: Bendamustine (Belrapzo, Bendeka, Treanda, Vivimusta)

Reference Number: LA.PHAR.307

Effective Date: 10.02.22

Last Review Date: 06.02.23~~07.22~~

Line of Business: Medicaid

[Coding Implications](#)[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

****Please note: This policy is for medical benefit****

Description

Bendamustine hydrochloride (Belrapzo®, Bendeka®, Treanda®) ~~→~~ Vivimusta™ is an alkylating drug.

FDA Approved Indication(s)

Belrapzo, Bendeka, ~~and~~ Treanda, and Vivimusta are indicated for the treatment of patients with:

- Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established.
- Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

Policy/Criteria

~~Prior authorization is required.~~ Provider must submit documentation (such as office chart notes and lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of Louisiana HealthCare Connections® ~~health plans affiliated with Centene Corporation®~~ that Belrapzo, Bendeka, and Treanda are **medically necessary** when the following criteria are met:

I. Initial Approval Criteria**A. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (must meet all):**

1. Diagnosis of chronic lymphocytic leukemia (CLL) (i.e., small lymphocytic lymphoma [SLL]);
2. Prescribed by or in consultation with an oncologist or hematologist;
3. Age ≥ 18 years;
4. Prescribed in combination with rituximab, Arzerra®, or Gazyva®;
5. Request meets one of the following (a or b):*
 - a. Dose does not exceed 100 mg/m² on Days 1 and 2 of a 28-day cycle, up to 6 cycles;
 - b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

*Prescribed regimen must be FDA-approved or recommended by NCCN

Approval duration:

~~Medicaid~~—6 months

CLINICAL POLICY

Bendamustine

B. Non-Hodgkin B-Cell Lymphomas (must meet all):

1. One of the following diagnoses (a through k):
 - a. Indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen;
 - b. Follicular lymphoma;
 - c. Gastric MALT lymphoma;
 - d. Nongastric MALT lymphoma;
 - e. Nodal marginal zone lymphoma;
 - f. Splenic marginal zone lymphoma;
 - g. Mantle cell lymphoma;
 - h. Diffuse large B-cell lymphoma (DLBCL) (*as subsequent therapy*);*
 - i. AIDS-related B-cell lymphoma (*as subsequent therapy*);*
 - j. Monomorphic post-transplant lymphoproliferative disorder (PTLD) (B-cell type) (*as subsequent therapy*);*
 - k. High-grade B-cell lymphomas: not otherwise specified or with translocations of MYC and BCL2 and/or BCL6 (double/triple hit lymphoma) (*as subsequent therapy*);*
- *See Appendix B - prior authorization may be required for prior therapies
2. Prescribed by or in consultation with an oncologist or hematologist;
3. Age \geq 18 years;
4. For nodal/splenic marginal zone lymphoma or gastric/nongastric MALT lymphoma, prescribed in combination with rituximab or Gazyva*;
5. For mantle cell lymphoma, prescribed in combination with rituximab;
6. Request meets one of the following (a or b):*
 - a. Dose does not exceed 120 mg/m² on Days 1 and 2 of a 21-day cycle, up to 8 cycles;
 - b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

*Prescribed regimen must be FDA-approved or recommended by NCCN

Approval duration:

Medicaid—6 months

C. NCCN Recommended Uses (off-label) (must meet all):

1. Diagnosis of one of the following (a, b, c, d, e, ~~or f~~, or g):
 - a. Classic or nodular lymphocyte-predominant Hodgkin lymphoma (HL) (*as subsequent therapy*);*
 - b. Pediatric HL (*as re-induction or subsequent therapy*);*
 - c. Multiple myeloma (MM);
 - d. T-cell lymphomas (i, ii, iii, or iv):
 - i. Hepatosplenic T-cell lymphoma (HSTCL) (*as subsequent therapy*);*
 - ii. Adult T-cell leukemia/lymphoma (ATLL) (*as subsequent therapy*);*
 - iii. Peripheral T-cell lymphoma (PTCL) (*as subsequent therapy*);*
- relapsed/refractory ALCL, peripheral T-cell lymphoma not otherwise

CLINICAL POLICY

Bendamustine

specified, angioimmunoblastic T-cell lymphoma, enteropathy-associated T-cell lymphoma, monomorphic epitheliotropic intestinal T-cell lymphoma, nodal peripheral T-cell lymphoma with T-follicular helper (TFH) phenotype, or follicular T-cell lymphoma;

iv. Breast implant-associated ALCL (as subsequent therapy);*

e.—

~~d. Primary cutaneous lymphomas (i or ii):~~

~~— Primary cutaneous CD30+ T-cell lymphoproliferative disorder (as subsequent therapy)*; primary cutaneous anaplastic large cell lymphoma (ALCL);~~

~~ii. Mycosis fungoides (MF)/Sezary syndrome (SS)~~

~~g. T-cell lymphomas (i, ii, iii, or iv):~~

~~— Hepatosplenic T-cell lymphoma (HSTCL) (as subsequent therapy);*~~

~~— Adult T-cell leukemia/lymphoma (ATLL) (as subsequent therapy);*~~

~~— Peripheral T-cell lymphoma (PTCL) (as subsequent therapy)*:
relapsed/refractory ALCL, peripheral T-cell lymphoma not otherwise specified, angioimmunoblastic T-cell lymphoma, enteropathy-associated T-cell lymphoma, monomorphic epitheliotropic intestinal T-cell lymphoma, nodal peripheral T-cell lymphoma with T-follicular helper (TFH) phenotype, or follicular T-cell lymphoma;~~

~~— Breast implant-associated ALCL (as subsequent therapy);*~~

e. Waldenstrom's macroglobulinemia (i.e., lymphoplasmacytic lymphoma);

f. Systemic light chain amyloidosis (SLCA) in combination with dexamethasone (as subsequent therapy);*

g. Hematopoietic cell transplantation in combination with etoposide, cytarabine, and melphalan for NHL without central nervous system (CNS) disease or for HL;

**See Appendix B - prior authorization may be required for prior therapies*

2. Prescribed by or in consultation with an oncologist or hematologist;

3. Age ≥ 18 years, unless diagnosis is pediatric HL;

4. Dose is within FDA maximum limit for any FDA-approved indication or is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (prescriber must submit supporting evidence).*

**Prescribed regimen must be FDA-approved or recommended by NCCN*

Approval duration:

Medicaid—6 months

D. Other diagnoses/indications (must meet 1 or 2):

1. If this drug has recently (within the last 6 months) undergone a label change (e.g., newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to LA.PMN.255

2. If the requested use (e.g., diagnosis, age, dosing regimen) is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized) AND criterion 1 above does not apply, refer to the off-label use policy LA.PMN.53

CLINICAL POLICY

Bendamustine

- ~~1. Refer to the off-label use policy if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): LA.PMN.53 for Medicaid.~~

II. Continued Therapy

A. All Indications in Section I (must meet all):

1. Currently receiving medication via Centene benefit, or documentation supports that member is currently receiving [Belrapzo](#), Bendeka, ~~or~~ Treanda [or Vivimusta](#) for a covered indication and has received this medication for at least 30 days;
2. Member is responding positively to therapy;
3. If request is for a dose increase, request meets (a or b):*
 - a. New dose does not exceed (i or ii):
 - i. CLL/SLL: 100 mg/m² on Days 1 and 2 of a 28-day cycle, up to 6 cycles;
 - ii. Non-Hodgkin indolent B-cell lymphoma: 120 mg/m² on Days 1 and 2 of a 21-day cycle, up to 8 cycles;
 - b. New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

*Prescribed regimen must be FDA-approved or recommended by NCCN

Approval duration:

~~Medicaid~~—12 months

B. Other diagnoses/indications (must meet 1 or 2):

- ~~1. If this drug has recently (within the last 6 months) under a label change (e.g. newly approved indication, age expansion, new dosing regimen) that is not yet reflected in this policy, refer to LA.PMN.255 Currently receiving medication via Louisiana Healthcare Connections benefit and documentation supports positive response to therapy.~~
- ~~2.1. Approval duration: Duration of request or 6 months (whichever is less); or~~
- ~~2. If requested use (e.g., diagnosis, age, dosing regimen) Refer to the off-label use policy if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): AND criterion 1 above does not apply, refer to the off-label use policy LA.PMN.53 for Medicaid.~~

~~C. Currently receiving medication via Louisiana Healthcare Connections benefit and documentation supports positive response to therapy. Approval duration: Duration of request or 6 months (whichever is less); or~~

- ~~1. Refer to the off-label use policy if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): LA.PMN.53 for Medicaid.~~

III. Diagnoses/Indications for which coverage is NOT authorized:

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policy ~~yes~~—LA.PMN.53 ~~for Medicaid or evidence of coverage documents.~~

CLINICAL POLICY

Bendamustine

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

ALCL: anaplastic large cell lymphoma
 ATLL: adult T-cell leukemia/lymphoma
 CLL: chronic lymphocytic leukemia
CNS: central nervous system
 DLBCL: diffuse large B-cell lymphoma
 FDA: Food and Drug Administration
 HL: Hodgkin lymphoma
 HSTCL: hepatosplenic gamma-delta T-cell lymphoma
 MF: mycosis fungoides

MM: multiple myeloma
 NCCN: National Comprehensive Cancer Network
 NHL: non-Hodgkin lymphoma
 PTCL: peripheral T-cell lymphoma
 PTLD: post-transplant lymphoproliferative disorder
SLCA: systemic light chain amyloidosis
 SLL: small lymphocytic lymphoma
 SS: Sezary syndrome

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may require prior authorization.

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
Examples of primary therapies (NCCN)		
DLBCL		
RCHOP (Rituxan® [rituximab], cyclophosphamide, doxorubicin, vincristine, prednisone)	Varies	Varies
EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) + Rituxan® (rituximab)	Varies	Varies
AIDS-related B-cell lymphoma		
EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) + Rituxan® (rituximab)	Varies	Varies
CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) + Rituxan® (rituximab)	Varies	Varies
PTCL		
CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)	Varies	Varies
EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin)	Varies	Varies
ATLL		
CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)	Varies	Varies
HyperCVAD (cyclophosphamide, vincristine, doxorubicin, dexamethasone) alternating with high-dose methotrexate and cytarabine	Varies	Varies
HSTCL		

CLINICAL POLICY

Bendamustine

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
DHAP (dexamethasone, cisplatin, cytarabine)	Varies	Varies
ICE (ifosfamide, carboplatin, etoposide)	Varies	Varies
MM		
Bortezomib/liposomal doxorubicin/dexamethasone	Varies	Varies
Carfilzomib/lenalidomide/dexamethasone	Varies	Varies
Daratumumab/bortezomib /dexamethasone	Varies	Varies
Monomorphic PTLD (B-cell type)		
RCHOP (Rituxan® [rituximab], cyclophosphamide, doxorubicin, vincristine, prednisone)	Varies	Varies
RCEPP (Rituxan® [rituximab], cyclophosphamide, etoposide, prednisone, procarbazine)	Varies	Varies

Therapeutic alternatives are listed as Brand name® (generic) when the drug is available by brand name only and generic (Brand name®) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s):
 - Belrapzo, Bendeka: patients with a history of a hypersensitivity reaction to bendamustine, polyethylene glycol 400, propylene glycol, or monothioglycerol
 - Treanda: patients with a history of a hypersensitivity reaction to bendamustine
 - Vivimusta: patients with a history of a hypersensitivity reaction to bendamustine, polyethylene glycol 400, dehydrated alcohol, or monothioglycerol
- Boxed warning(s): none reported

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
CLL/SLL*	Bendeka: 100 mg/m ² IV over 10 minutes on Days 1 and 2 of a 28-day cycle, up to 6 cycles Belrapzo, Treanda: 100 mg/m ² IV over 30 minutes on days 1 and 2 of a 28-day cycle, up to 6 cycles <u>Vivimusta: 100 mg/m² IV over 20 minutes on Days 1 and 2 of a 28-day cycle, up to 6 cycles</u>	See regimen
Indolent B-cell lymphoma*	Bendeka: 120 mg/m ² IV over 10 minutes on Days 1 and 2 of a 21-day cycle, up to 8 cycles Belrapzo, Treanda: 120 mg/m ² IV over 60 minutes on days 1 and 2 of a 21-day cycle, up to 8 cycles	See regimen

CLINICAL POLICY

Bendamustine

Indication	Dosing Regimen	Maximum Dose
	<u>Vivimusta: 120 mg/m² IV over 20 minutes on Days 1 and 2 of a 21-day cycle, up to 8 cycles</u>	

**Non-Hodgkin lymphomas*

VI. Product Availability

Drug Name	Availability
Bendamustine (Belrapzo, Bendeka, Vivimusta)	Solution (multiple-dose vial): 100 mg/4 mL
Bendamustine (Treanda)	Solution (single-dose vial): 45 mg/0.5 mL; 180 mg/2 mL Lyophilized powder (single-dose vial): 25 mg in a 20 mL vial; 100 mg in a 20 mL vial

VII. References

1. Belrapzo Prescribing Information. Woodcliff Lake, NJ: Eagle Pharmaceuticals, Inc; June 2022. Available at: www.belrapzo.com. Accessed June 24, 2022.
2. Bendeka Prescribing Information. North Wales, PA: Teva Pharmaceuticals USA, Inc.; October 2021. Available at: <http://www.bendeka.com/>. Accessed June 24, 2022.
3. Treanda Prescribing Information. North Wales, PA: Teva Pharmaceuticals USA, Inc.; June 2021. Available at: <http://treandahcp.com/>. Accessed June 24, 2022.
4. Vivimusta Prescribing Information. Princeton, NJ: Slayback Pharma; December 2022. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/212209s0001b1.pdf. Accessed December 27, 2022.
5. National Comprehensive Cancer Network Drugs and Biologics Compendium. Available at: http://www.nccn.org/professionals/drug_compendium. Accessed June 24, 2022.
6. National Comprehensive Cancer Network. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Version 3.2022. Available at: https://www.nccn.org/professionals/physician_gls/pdf/cll.pdf. Accessed June 24, 2022.
7. National Comprehensive Cancer Network. B-cell Lymphomas Version 4.2022. Available at: https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf. Accessed June 24, 2022.
8. National Comprehensive Cancer Network. Hodgkin Lymphoma Version 2.2022. Available at: https://www.nccn.org/professionals/physician_gls/pdf/hodgkins.pdf. Accessed June 24, 2022.
9. National Comprehensive Cancer Network. Multiple Myeloma Version 5.2022. Available at: https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf. Accessed June 24, 2022.
10. National Comprehensive Cancer Network. T-cell Lymphomas Version 2.2022. Available at: https://www.nccn.org/professionals/physician_gls/pdf/t-cell.pdf. Accessed June 24, 2022.
11. National Comprehensive Cancer Network. Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma Version 3.2022. Available at: https://www.nccn.org/professionals/physician_gls/pdf/waldenstroms.pdf. Accessed June 24, 2022.

CLINICAL POLICY

Bendamustine

1. ~~Belrapzo Prescribing Information. Woodcliff Lake, NJ: Eagle Pharmaceuticals, Inc.; November 2020. Available at: www.belrapzo.com. Accessed July 15, 2021.~~
2. ~~Bendeka Prescribing Information. North Wales, PA: Teva Pharmaceuticals USA, Inc.; November 2020. Available at: <http://www.bendeka.com/>. Accessed July 13, 2021.~~
3. ~~Treanda Prescribing Information. North Wales, PA: Teva Pharmaceuticals USA, Inc.; July 2021. Available at: <http://treandahep.com/>. Accessed July 13, 2021.~~
4. ~~National Comprehensive Cancer Network Drugs and Biologics Compendium. Available at: http://www.nccn.org/professionals/drug_compendium. Accessed June 28, 2021.~~
5. ~~National Comprehensive Cancer Network. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Version 4.2021. Available at: https://www.nccn.org/professionals/physician_gls/pdf/ell.pdf. Accessed July 13, 2021.~~
6. ~~National Comprehensive Cancer Network. B-cell Lymphomas Version 4.2021. Available at: https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf. Accessed July 13, 2021.~~
7. ~~National Comprehensive Cancer Network. Hodgkin Lymphoma Version 4.2021. Available at: https://www.nccn.org/professionals/physician_gls/pdf/hodgkins.pdf. Accessed July 13, 2021.~~
8. ~~National Comprehensive Cancer Network. Multiple Myeloma Version 7.2021. Available at: https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf. Accessed July 13, 2021.~~
9. ~~National Comprehensive Cancer Network. Primary Cutaneous Lymphomas Version 2.2021. Available at: https://www.nccn.org/professionals/physician_gls/pdf/primary_cutaneous.pdf. Accessed July 13, 2021.~~
10. ~~National Comprehensive Cancer Network. T-cell Lymphomas Version 1.2021. Available at: https://www.nccn.org/professionals/physician_gls/pdf/t-cell.pdf. Accessed July 13, 2021.~~
11. ~~National Comprehensive Cancer Network. Waldenstrom Macroglobulinemia/Lymphoplasmacytic Lymphoma Version 1.2022. Available at: https://www.nccn.org/professionals/physician_gls/pdf/waldenstroms.pdf. Accessed July 13, 2021.~~

Coding Implications

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description
J9033	Injection, bendamustine HCl (Treanda), 1 mg
J9034	Injection, bendamustine HCl (Bendeka), 1 mg
J9036	Injection, bendamustine HCl, (Belrapzo), 1 mg
<u>C9399</u>	<u>Unclassified drugs or biologicals (Vivimusta)</u>
<u>J9999</u>	<u>Not otherwise classified, antineoplastic drugs (Vivimusta)</u>

CLINICAL POLICY

Bendamustine

Reviews, Revisions, and Approvals	Date	LDH Approval Date
Converted corporate to local policy	07.22	10.02.22
Added new dosage form Vivimusta Updated applicable HCPCS Codes Added SLCA and hematopoietic cell transplantation under NCCN recommended use given category 2A recommendation. Removed primary cutaneous lymphomas as use is no longer supported by NCCN primary cutaneous lymphoma guideline. References reviewed and updated. Template changes applied to other diagnoses/indications.	06.02.23	

Important Reminder

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. LHCC makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable LHCC administrative policies and procedures.

This clinical policy is effective as of the date determined by LHCC. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. LHCC retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to

CLINICAL POLICY

Bendamustine

recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom LHCC has no control or right of control. Providers are not agents or employees of LHCC.

This clinical policy is the property of LHCC. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

©2020 Louisiana Healthcare Connections. All rights reserved. All materials are exclusively owned by Louisiana Healthcare Connections and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Louisiana Healthcare Connections. You may not alter or remove any trademark, copyright or other notice contained herein. Louisiana Healthcare Connections is a registered trademark exclusively owned by Louisiana Healthcare Connections.